Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001477932-25-001919·CytoMed Therapeutics Ltd
Schedule 13G ownership disclosure
CYTOMED THERAPEUTICS LIMITED
Ordinary Shares, no par value per share · CUSIP: Y1R80M106
Event date: 2024-12-16
- Filing-level shares
- 1,307,933
- Percent of class
- 11.33%
- mDR LTD
Shares: 1,307,933 · Class: 11.33%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001477932-25-001919
- Form type
- SCHEDULE 13G/A
- Filer
- CytoMed Therapeutics Ltd
- CIK
- CIK 1873093
- Filed
- Mar 24, 2025
- Reporting period
- Dec 16, 2024
- Description
- Schedule 13G beneficial ownership